MA44484A - Biomarqueurs de protéinopathies et utilisations associées - Google Patents

Biomarqueurs de protéinopathies et utilisations associées

Info

Publication number
MA44484A
MA44484A MA044484A MA44484A MA44484A MA 44484 A MA44484 A MA 44484A MA 044484 A MA044484 A MA 044484A MA 44484 A MA44484 A MA 44484A MA 44484 A MA44484 A MA 44484A
Authority
MA
Morocco
Prior art keywords
proteinopathy
biomarkers
associated uses
proteinopathy biomarkers
Prior art date
Application number
MA044484A
Other languages
English (en)
Inventor
Sergio Pablo Sardi
Clemens Scherzer
Original Assignee
Genzyme Corp
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Brigham & Womens Hospital Inc filed Critical Genzyme Corp
Publication of MA44484A publication Critical patent/MA44484A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
MA044484A 2016-03-25 2017-03-24 Biomarqueurs de protéinopathies et utilisations associées MA44484A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662313638P 2016-03-25 2016-03-25
US201662372523P 2016-08-09 2016-08-09

Publications (1)

Publication Number Publication Date
MA44484A true MA44484A (fr) 2019-01-30

Family

ID=58547821

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044484A MA44484A (fr) 2016-03-25 2017-03-24 Biomarqueurs de protéinopathies et utilisations associées

Country Status (10)

Country Link
US (1) US20200124624A1 (fr)
EP (1) EP3433623A2 (fr)
JP (2) JP6940515B2 (fr)
KR (1) KR20180124971A (fr)
AU (1) AU2017238769A1 (fr)
CA (1) CA3018745A1 (fr)
IL (1) IL261906A (fr)
MA (1) MA44484A (fr)
MX (1) MX2018011679A (fr)
WO (1) WO2017165766A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021173962A1 (fr) * 2020-02-28 2021-09-02 Genemo, Inc. Méthodes et matériaux pour le diagnostic et le traitement d'un trouble neuronal
CN112798727B (zh) * 2021-04-09 2021-07-06 宝枫生物科技（北京）有限公司 用于诊断脑白质病变的生物标志物f7及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8781557B2 (en) 1999-08-11 2014-07-15 Osteoplastics, Llc Producing a three dimensional model of an implant
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20050191685A1 (en) 2004-02-24 2005-09-01 Innogenetics N.V. Method for determining the risk of developing a neurological disease
GB2414309B (en) 2004-05-18 2009-02-25 Simon Richard Daniel Spherical display and control device
EP3284469B1 (fr) 2006-09-12 2020-11-04 Genzyme Corporation Compositions et procédés de détection de la maladie lysosomale congénitale
EP2594564B1 (fr) 2007-05-31 2016-09-28 Genzyme Corporation Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol
US8026099B2 (en) 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders
KR101687039B1 (ko) 2008-10-03 2016-12-15 젠자임 코포레이션 2-아실아미노프로판올형 글루코실세라미드 합성효소 억제제
CA2745451A1 (fr) * 2008-11-14 2010-05-20 Parkinson's Institute Compositions et procedes pour le traitement d'une fonction alteree de l'a-synucleine
AU2011281017A1 (en) * 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting neurological or neuropsychiatric diseases or conditions
DK2685986T3 (da) * 2011-03-18 2020-03-02 Genzyme Corp Glucosylceramidsyntasehæmmer
CN103764166B (zh) * 2011-06-22 2017-10-24 通用医疗公司 蛋白质病的治疗
WO2013070953A1 (fr) 2011-11-08 2013-05-16 University Of Washington Procédés et compositions d'analyse d'enzymes lysosomales

Also Published As

Publication number Publication date
AU2017238769A1 (en) 2018-11-15
MX2018011679A (es) 2019-06-24
JP7250081B2 (ja) 2023-03-31
WO2017165766A2 (fr) 2017-09-28
CA3018745A1 (fr) 2017-09-28
JP6940515B2 (ja) 2021-09-29
KR20180124971A (ko) 2018-11-21
IL261906A (en) 2018-10-31
EP3433623A2 (fr) 2019-01-30
JP2019513231A (ja) 2019-05-23
US20200124624A1 (en) 2020-04-23
JP2021185377A (ja) 2021-12-09
WO2017165766A3 (fr) 2017-11-02

Similar Documents

Publication Publication Date Title
MA50502A (fr) Adénovirus et utilisations associées
MA50618A (fr) Polyrhérapies et leurs utilisations
MA46700A (fr) Variants polypeptidiques et ses utilisations
DE202018003363U8 (de) Handgelenkssphygmomanometer
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
DK3642340T3 (da) Modificeret L-asparaginase
CL2018000524S1 (es) Golilla
DK3351526T3 (da) Diisopentylterephthalat
DK3471609T3 (da) Kvantitativ seismokardiografi
MA43957A (fr) Biomarqueurs de copanlisib
MA43958A (fr) Biomarqueurs copanlisib
MA47019A (fr) Agents, utilisations et procédés
MA49905A (fr) Polyesteramines et polyesterquats
DK3262182T3 (da) Modificeret creatinase
KR20180085008A (ko) 항-pcsk9 항체 및 그의 용도
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
DK3672948T3 (da) Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser
MA41022A (fr) Ciblage lysosomial et utilisations correspondantes
DK3576686T3 (da) Brokbind
UA34707S (uk) Всюдихід
MA44484A (fr) Biomarqueurs de protéinopathies et utilisations associées
DK3391870T3 (da) Pneumomassagehylster
FI11006U1 (fi) Paneelijärjestelmä ja sen paneeli
DK3672967T3 (da) Azaindolylpyridon- og diazaindolylpyridonforbindelser